Gastric cancer patient with MET amplification treated with crizotinib achieves long-term survival: a case report.

ABSTRACT:

Background

Gastric cancer (GC) is one of the leading contributors to global malignancies incidence and mortality worldwide. Advanced GC had a relatively poor prognosis. The emerging of targeted therapy improved the survival and prognosis of GC patients. In the treatment of GC, crizotinib, although an unapproved drug, has shown satisfactory treatment benefits in some cases.

Case description

A GC hepatocyte growth factor receptor (MET) amplification patient with extensive abdominal cavity metastasis who was diagnosed as intermediate-low differentiated adenocarcinoma. After 34 months of treatment with crizotinib, the patient's MET gene amplification mutation disappeared and gained high-quality life during this period. However, based on new testing evidence, the pa

SUBMITTER: Xu W 

PROVIDER: S-EPMC11761320 | biostudies-literature | 2025

REPOSITORIES: biostudies-literature